Imagion Biosystems Limited (ASX:IBX), a company dedicated to improving healthcare through earlier cancer detection, today announced the commercial launch of PEG-coated nanoparticles as the latest product in its exclusive line of PrecisionMRX® brand nanoparticles.
The new PEG-coated nanoparticles are composed of a polymer-encapsulated 25 nm iron oxide core with a monolayer of methoxypolyethylene glycol (mPEG). This unique coating acts as a steric barrier to protein adsorption, which results in reduced uptake by macrophages, a feature desired by life scientists seeking improved circulation times for in vivo applications such as magnetic particle imaging.
The “stealth” property of the PEG-coated iron oxide nanoparticles has been reported in pre-clinical studies involving the development of MagSense™ superparamagnetic relaxometry technology for earlier cancer detection. Pharmacokinetic data reported at the 2017 World Medical Imaging Congress showed that after 24 hours in circulation, only 10% of injected particles were immobilized in the liver.
Like all PrecisionMRX® brand nanoparticles, the new PEG-coated nanoparticles are manufactured in-house by Imagion Biosystems to ensure narrow size dispersity. Each lot of PrecisionMRX® nanoparticles is thoroughly characterized for particle size, hydrodynamic diameter, and zeta potential. These lot-specific measurements are recorded on a Certificate of Analysis, which is included with every PrecisionMRX® product shipment.
For additional information, visit the mPEG Coated PrecisionMRX Nanoparticles product page.
PrecisionMRX® nanoparticles are for research use only.